An Analysis of the Social and Economic Costs of Breast Cancer in Italy.
breast cancer
health economics
hospital
social security
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
26 08 2021
26 08 2021
Historique:
received:
07
06
2021
revised:
06
08
2021
accepted:
18
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Breast cancer is the most prevalent cancer affecting women and it represents an important economic burden. The aim of this study was to estimate the socio-economic burden of breast cancer (BC) in Italy both from the National Health Service (NHS) and the government perspectives (costs borne by the social security system). The economic analysis was based on the costs incurred by the NHS from 2008 to 2016 (direct costs related to hospitalizations) and by the National Social Security Institute (INPS) from 2009 to 2015 (costs of social security benefits) for patients with breast cancer. The analysis was based on the Hospital Information System (HIS) and Disability Insurance Awards databases. For both databases, patients affected by a malignant neoplasm of the female breast, carcinoma in situ, or secondary malignant neoplasm of the breast were considered. Results show that more than 75,000 women were hospitalized for breast cancer every year, with an overall cost for hospitalization of about €300 million per year. From the Social Security analysis, a number of 29,000 beneficiaries each year was estimated. Considering per patient social costs, breast cancer at the primary stage cost €8828 per year, while secondary neoplasms cost €9780, with an average total economic burden of €257 million per year. This analysis focused on the economic impact of breast cancer in Italy, showing that an advanced stage of the disease was associated with a higher cost.
Sections du résumé
BACKGROUND
Breast cancer is the most prevalent cancer affecting women and it represents an important economic burden. The aim of this study was to estimate the socio-economic burden of breast cancer (BC) in Italy both from the National Health Service (NHS) and the government perspectives (costs borne by the social security system).
METHODS
The economic analysis was based on the costs incurred by the NHS from 2008 to 2016 (direct costs related to hospitalizations) and by the National Social Security Institute (INPS) from 2009 to 2015 (costs of social security benefits) for patients with breast cancer. The analysis was based on the Hospital Information System (HIS) and Disability Insurance Awards databases. For both databases, patients affected by a malignant neoplasm of the female breast, carcinoma in situ, or secondary malignant neoplasm of the breast were considered.
RESULTS
Results show that more than 75,000 women were hospitalized for breast cancer every year, with an overall cost for hospitalization of about €300 million per year. From the Social Security analysis, a number of 29,000 beneficiaries each year was estimated. Considering per patient social costs, breast cancer at the primary stage cost €8828 per year, while secondary neoplasms cost €9780, with an average total economic burden of €257 million per year.
CONCLUSIONS
This analysis focused on the economic impact of breast cancer in Italy, showing that an advanced stage of the disease was associated with a higher cost.
Identifiants
pubmed: 34501588
pii: ijerph18179005
doi: 10.3390/ijerph18179005
pmc: PMC8431604
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Breast Cancer. 2020 Nov 9;:
pubmed: 33342749
Clin Drug Investig. 2020 May;40(5):449-458
pubmed: 32248346
Breast Cancer Res Treat. 2009 Jul;116(1):201-7
pubmed: 18683041
Clin Ter. 2015;166(3):e177-81
pubmed: 26152629
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Curr Oncol. 2014 Dec;21(6):281-93
pubmed: 25489255
Breast Cancer Res Treat. 2008 May;109(2):367-77
pubmed: 17674201
Pharmacoeconomics. 2003;21(6):383-96
pubmed: 12678566
PLoS One. 2018 Nov 26;13(11):e0207993
pubmed: 30475890
Reumatismo. 2015 Sep 16;67(2):45-56
pubmed: 26492962
BMC Cancer. 2018 Mar 7;18(1):262
pubmed: 29514651
Pharmacoeconomics. 2009;27(3):199-209
pubmed: 19354340
Clin Drug Investig. 2019 Oct;39(10):945-951
pubmed: 31347036
Breast. 2021 Jun;57:49-61
pubmed: 33774459
Eur J Health Econ. 2011 Aug;12(4):311-7
pubmed: 20306109
Clin Breast Cancer. 2021 Jun;21(3):e168-e176
pubmed: 33357965
Int J Environ Res Public Health. 2020 Dec 05;17(23):
pubmed: 33291364